ADC Therapeutics SA
ADCT
$3.69
-$0.26-6.53%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.43M | 18.84M | 23.03M | 16.91M | 18.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.43M | 18.84M | 23.03M | 16.91M | 18.46M |
| Cost of Revenue | 28.01M | 30.93M | 2.06M | 28.47M | 33.35M |
| Gross Profit | -11.58M | -12.09M | 20.97M | -11.56M | -14.89M |
| SG&A Expenses | 19.01M | 18.97M | 20.51M | 20.87M | 20.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.02M | 49.90M | 51.50M | 49.35M | 54.03M |
| Operating Income | -30.59M | -31.06M | -28.46M | -32.44M | -35.56M |
| Income Before Tax | -40.97M | -55.39M | -38.44M | -31.05M | -43.88M |
| Income Tax Expenses | -- | 1.25M | 165.00K | -321.00K | 90.00K |
| Earnings from Continuing Operations | -40.97M | -56.65M | -38.60M | -30.73M | -43.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.97M | -56.65M | -38.60M | -30.73M | -43.97M |
| EBIT | -30.59M | -31.06M | -28.46M | -32.44M | -35.56M |
| EBITDA | -30.59M | -30.69M | -28.12M | -32.10M | -35.23M |
| EPS Basic | -0.30 | -0.50 | -0.36 | -0.29 | -0.42 |
| Normalized Basic EPS | -0.19 | -0.23 | -0.22 | -0.18 | -0.26 |
| EPS Diluted | -0.30 | -0.50 | -0.36 | -0.29 | -0.42 |
| Normalized Diluted EPS | -0.19 | -0.23 | -0.22 | -0.18 | -0.26 |
| Average Basic Shares Outstanding | 136.45M | 113.74M | 107.20M | 105.40M | 104.82M |
| Average Diluted Shares Outstanding | 136.45M | 113.74M | 107.20M | 105.40M | 104.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |